Correlates and assessment of excess cardiovascular risk in bronchiectasis
- 16 November 2017
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 50 (5), 1701127
- https://doi.org/10.1183/13993003.01127-2017
Abstract
Patients with bronchiectasis are at increased risk of cardiovascular disease. We aimed to identify factors associated with elevated cardiovascular risk in bronchiectasis, measured using aortic stiffness and cardiac biomarkers. In addition, we sought to compare these direct measures against calculated QRISK2 scores. Aortic stiffness, cardiac biomarkers and systemic inflammation were measured in 101 adults with stable bronchiectasis. In addition, clinical and demographic data were collected to allow calculation of QRISK2 score and the bronchiectasis severity index (BSI) for each patient. The BSI score correlated with measured cardiovascular risk assessments, partly due to greater exacerbation frequency and lower forced expiratory volume in 1 s. Pulse-wave velocity was significantly higher in frequent exacerbators (≥3 events·year-1) than infrequent exacerbators (-1; 10.5 versus 9.2 m·s−1, p=0.01). In addition, frequent exacerbators had elevated serum C-reactive protein concentration, suggesting increased systemic inflammation (4.8 versus 2.2 mg·L−1, p=0.005). QRISK2 systematically underestimated cardiovascular risk in this population (median change in relative risk 1.29). Underestimation was associated with frequent exacerbations and male sex. Patients with bronchiectasis have greater cardiovascular risk than published reference populations. Excess cardiovascular risk is associated with exacerbation frequency and impaired lung function. Cardiovascular risk assessment in bronchiectasis should be individualised, as calculation tools are likely to underestimate the risk in this population.Keywords
Funding Information
- National Institute for Health Research (F180)
This publication has 44 references indexed in Scilit:
- Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort studyThe Lancet Respiratory Medicine, 2016
- Bronchiectasis and the risk of cardiovascular disease: a population-based studyThorax, 2016
- Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidanceBMJ, 2014
- Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Systemic comorbidities in bronchiectasisChronic Respiratory Disease, 2012
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionNew England Journal of Medicine, 2012
- Trends in bronchiectasis mortality in England and WalesRespiratory Medicine, 2010
- British Thoracic Society guideline for non-CFbronchiectasisThorax, 2010
- Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2BMJ, 2008
- Systemic markers of inflammation in stable bronchiectasisEuropean Respiratory Journal, 1998